NASDAQ:TALS Talaris Therapeutics (TALS) Stock Forecast, Price & News $2.85 -0.02 (-0.70%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$2.83▼$2.9250-Day Range$2.68▼$3.0852-Week Range$0.89▼$3.29Volume67,276 shsAverage Volume400,359 shsMarket Capitalization$121.87 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Talaris Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside163.2% Upside$7.50 Price TargetShort InterestHealthy2.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector668th out of 969 stocksBiological Products, Except Diagnostic Industry106th out of 161 stocks 3.0 Analyst's Opinion Consensus RatingTalaris Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, Talaris Therapeutics has a forecasted upside of 163.2% from its current price of $2.85.Amount of Analyst CoverageTalaris Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.79% of the float of Talaris Therapeutics has been sold short.Short Interest Ratio / Days to CoverTalaris Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Talaris Therapeutics has recently increased by 24.10%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTalaris Therapeutics does not currently pay a dividend.Dividend GrowthTalaris Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TALS. Previous Next 1.9 News and Social Media Coverage News SentimentTalaris Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Talaris Therapeutics this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Talaris Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.50% of the stock of Talaris Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.61% of the stock of Talaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Talaris Therapeutics is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Talaris Therapeutics is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTalaris Therapeutics has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Talaris Therapeutics (NASDAQ:TALS) StockTalaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.Read More TALS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TALS Stock News HeadlinesSeptember 12, 2023 | finance.yahoo.comWe're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn RateAugust 15, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOTSeptember 28, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. August 14, 2023 | finance.yahoo.comImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance BusinessAugust 8, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURFJuly 28, 2023 | benzinga.comMoore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law FirmJuly 27, 2023 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Talaris Therapeutics, Inc. (TALS)July 18, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, QUOT, TALS, CFMSSeptember 28, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. July 18, 2023 | msn.comTalaris Therapeutics: Cashing Out Ahead Of Tourmaline MergerJuly 6, 2023 | msn.comTalaris Therapeutics (TALS) Price Target Increased by 66.67% to 12.75June 27, 2023 | markets.businessinsider.comIMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, DICE, NEX, NETIJune 26, 2023 | businesswire.comTALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALSJune 23, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Talaris Therapeutics, Inc. MergerJune 23, 2023 | bizjournals.comTalaris Therapeutics announces merger after layoffsJune 22, 2023 | bizjournals.comNY biotech to go public by merging with Boston firm that laid off 95% of staffJune 22, 2023 | msn.comTalaris jumps 29% on merger with Tourmaline Bio in all-stock dealJune 22, 2023 | markets.businessinsider.comIMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIRJune 22, 2023 | finanznachrichten.deTalaris Therapeutics, Inc.: Talaris Therapeutics and Tourmaline Bio Announce Merger AgreementJune 22, 2023 | msn.comTalaris Soars on All Stock Deal with Tourmaline BioJune 22, 2023 | stockhouse.comTALS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Talaris Therapeutics, Inc. Is Fair to ShareholdersJune 22, 2023 | benzinga.comWhy Talaris Therapeutics Stock Is Shooting Higher TodayJune 22, 2023 | seekingalpha.comTalaris to merge with Tourmaline Bio in all-stock dealJune 22, 2023 | markets.businessinsider.comTourmaline, Talaris Announce All-stock MergerJune 22, 2023 | finance.yahoo.comTalaris Therapeutics and Tourmaline Bio Announce Merger AgreementJune 15, 2023 | benzinga.comTalaris Therapeutics Board Member Awarded $50K Worth of Stock OptionsJune 15, 2023 | benzinga.comTalaris Therapeutics Director Awarded $50K Worth of Stock OptionsSee More Headlines Receive TALS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TALS Company Calendar Last Earnings8/14/2023Today9/28/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TALS CUSIPN/A CIK1827506 Webtalaristx.com Phone502-398-9250FaxN/AEmployees84Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.50 High Stock Price Forecast$12.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+163.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.93% Return on Assets-37.37% Debt Debt-to-Equity RatioN/A Current Ratio15.41 Quick Ratio15.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.33 per share Price / Book0.66Miscellaneous Outstanding Shares42,760,000Free Float35,708,000Market Cap$121.87 million OptionableNot Optionable Beta2.26 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMs. Mary Kay Fenton (Age 59)Interim CEO, Pres, CFO & Treasurer Comp: $598.98kDr. Suzanne T. Ildstad M.D. (Age 70)Founder, Member of Scientific Advisory Board, Sr. Scientific Advisor & Director Comp: $318.3kMs. Suzanne TollerudVP of Corp. Devel.Key CompetitorsINmune BioNASDAQ:INMBCentury TherapeuticsNASDAQ:IPSCOmega TherapeuticsNASDAQ:OMGASangamo TherapeuticsNASDAQ:SGMOTScan TherapeuticsNASDAQ:TCRXView All CompetitorsInsiders & InstitutionsAffinity Asset Advisors LLCBought 200,000 shares on 8/21/2023Ownership: 0.476%Walleye Capital LLCBought 304,599 shares on 8/15/2023Ownership: 0.725%Corsair Capital Management L.P.Bought 55,000 shares on 8/15/2023Ownership: 0.131%Y Intercept Hong Kong LtdBought 32,062 shares on 8/15/2023Ownership: 0.076%XTX Topco LtdBought 19,884 shares on 8/15/2023Ownership: 0.047%View All Insider TransactionsView All Institutional Transactions TALS Stock - Frequently Asked Questions Should I buy or sell Talaris Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Talaris Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TALS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TALS, but not buy additional shares or sell existing shares. View TALS analyst ratings or view top-rated stocks. What is Talaris Therapeutics' stock price forecast for 2023? 2 brokerages have issued 1 year price targets for Talaris Therapeutics' shares. Their TALS share price forecasts range from $3.00 to $12.00. On average, they expect the company's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 163.2% from the stock's current price. View analysts price targets for TALS or view top-rated stocks among Wall Street analysts. How have TALS shares performed in 2023? Talaris Therapeutics' stock was trading at $1.02 on January 1st, 2023. Since then, TALS shares have increased by 179.4% and is now trading at $2.85. View the best growth stocks for 2023 here. Are investors shorting Talaris Therapeutics? Talaris Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 593,800 shares, an increase of 24.1% from the August 31st total of 478,500 shares. Based on an average daily trading volume, of 308,800 shares, the days-to-cover ratio is currently 1.9 days. Currently, 2.8% of the company's stock are sold short. View Talaris Therapeutics' Short Interest. When is Talaris Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our TALS earnings forecast. How were Talaris Therapeutics' earnings last quarter? Talaris Therapeutics, Inc. (NASDAQ:TALS) posted its earnings results on Monday, August, 14th. The company reported ($0.20) earnings per share for the quarter. When did Talaris Therapeutics IPO? (TALS) raised $150 million in an initial public offering (IPO) on Friday, May 7th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO. What is Talaris Therapeutics' stock symbol? Talaris Therapeutics trades on the NASDAQ under the ticker symbol "TALS." Who are Talaris Therapeutics' major shareholders? Talaris Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (5.55%), BML Capital Management LLC (4.76%), Great Point Partners LLC (1.59%), JPMorgan Chase & Co. (1.08%), Renaissance Technologies LLC (1.05%) and Walleye Capital LLC (0.73%). Insiders that own company stock include Francois Nader, Longitude Capital Partners Iii, Sandip Agarwala, Scott Requadt and Suzanne Ildstad. View institutional ownership trends. How do I buy shares of Talaris Therapeutics? Shares of TALS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Talaris Therapeutics' stock price today? One share of TALS stock can currently be purchased for approximately $2.85. How much money does Talaris Therapeutics make? Talaris Therapeutics (NASDAQ:TALS) has a market capitalization of $121.87 million. The company earns $-73,890,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. How can I contact Talaris Therapeutics? The official website for the company is talaristx.com. The company can be reached via phone at 502-398-9250. This page (NASDAQ:TALS) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.